Roger Vilardaga Viera to Humans
This is a "connection" page, showing publications Roger Vilardaga Viera has written about Humans.
Connection Strength
0.459
-
Rubenstein D, Pacek LR, Smith C, McClernon FJ, Enyioha C, Vilardaga R. Stagnant daily smoking prevalence between 2008 and 2019 among Black and Hispanic adults with serious psychological distress. Drug Alcohol Depend. 2023 Jul 01; 248:109943.
Score: 0.047
-
Vilardaga R, McClernon FJ. Regulatory oversight of behavioral digital therapeutics for addiction treatment: A commentary on Khadjesari et al. Addiction. 2021 Dec; 116(12):3287-3289.
Score: 0.042
-
Browne J, Halverson TF, Vilardaga R. Engagement with a digital therapeutic for smoking cessation designed for persons with psychiatric illness fully mediates smoking outcomes in a pilot randomized controlled trial. Transl Behav Med. 2021 Sep 15; 11(9):1717-1725.
Score: 0.042
-
Vilardaga R, Rizo J, Palenski PE, Mannelli P, Oliver JA, Mcclernon FJ. Pilot Randomized Controlled Trial of a Novel Smoking Cessation App Designed for Individuals With Co-Occurring Tobacco Use Disorder and Serious Mental Illness. Nicotine Tob Res. 2020 Aug 24; 22(9):1533-1542.
Score: 0.039
-
Vilardaga R, Rizo J, Ries RK, Kientz JA, Ziedonis DM, Hernandez K, McClernon FJ. Formative, multimethod case studies of learn to quit, an acceptance and commitment therapy smoking cessation app designed for people with serious mental illness. Transl Behav Med. 2019 Nov 25; 9(6):1076-1086.
Score: 0.037
-
Luoma JB, Guinther PM, Lawless DesJardins NM, Vilardaga R. Is shame a proximal trigger for drinking? A daily process study with a community sample. Exp Clin Psychopharmacol. 2018 Jun; 26(3):290-301.
Score: 0.034
-
Sullivan M, Langford DJ, Davies PS, Tran C, Vilardaga R, Cheung G, Yoo D, McReynolds J, Lober WB, Tauben D, Vowles KE. A Controlled Pilot Trial of PainTracker Self-Manager, a Web-Based Platform Combined With Patient Coaching, to Support Patients' Self-Management of Chronic Pain. J Pain. 2018 Sep; 19(9):996-1005.
Score: 0.033
-
Villatte JL, Vilardaga R, Villatte M, Plumb Vilardaga JC, Atkins DC, Hayes SC. Acceptance and Commitment Therapy modules: Differential impact on treatment processes and outcomes. Behav Res Ther. 2016 Feb; 77:52-61.
Score: 0.028
-
Vilardaga R, Rizo J, Kientz JA, McDonell MG, Ries RK, Sobel K. User Experience Evaluation of a Smoking Cessation App in People With Serious Mental Illness. Nicotine Tob Res. 2016 May; 18(5):1032-8.
Score: 0.028
-
Vilardaga R, Heffner JL, Mercer LD, Bricker JB. Do counselor techniques predict quitting during smoking cessation treatment? A component analysis of telephone-delivered Acceptance and Commitment Therapy. Behav Res Ther. 2014 Oct; 61:89-95.
Score: 0.026
-
Cioe PA, Schnoll R, Hoeppner BB, Gross R, Hitsman BL, Leone FT, Ashare R, Vilardaga R, Tashima K, Pinkston M, Kahler CW. The Impact of the COVID-19 Pandemic on Stress, Isolation, Smoking Behaviors, and Motivation to Quit in People with HIV Who Smoke. AIDS Behav. 2023 Jun; 27(6):1862-1869.
Score: 0.011
-
Schnoll R, Bernstein SL, Kaufman A, Gross R, Catz SL, Cioe PA, Hitsman B, Marhefka SL, Pacek LR, Vidrine DJ, Vilardaga R, Edelman EJ, McClure JB, Ashare R, Lockhart E, Crothers K. COVID-19 Challenges Confronted by Smoking Cessation Clinical Trials for People Living With HIV: The Experience of Grantees of the US National Cancer Institute. Nicotine Tob Res. 2021 Aug 18; 23(9):1629-1632.
Score: 0.010
-
Ashare RL, Bernstein SL, Schnoll R, Gross R, Catz SL, Cioe P, Crothers K, Hitsman B, Marhefka SL, McClure JB, Pacek LR, Vidrine DJ, Vilardaga R, Kaufman A, Edelman EJ. The United States National Cancer Institute's Coordinated Research Effort on Tobacco Use as a Major Cause of Morbidity and Mortality among People with HIV. Nicotine Tob Res. 2021 Jan 22; 23(2):407-410.
Score: 0.010
-
Oliver JA, Hallyburton MB, Pacek LR, Mitchell JT, Vilardaga R, Fuemmeler BF, McClernon FJ. What Do Smokers Want in A Smartphone-Based Cessation Application? Nicotine Tob Res. 2018 Nov 15; 20(12):1507-1514.
Score: 0.009
-
McDonell MG, Leickly E, McPherson S, Skalisky J, Srebnik D, Angelo F, Vilardaga R, Nepom JR, Roll JM, Ries RK. A Randomized Controlled Trial of Ethyl Glucuronide-Based Contingency Management for Outpatients With Co-Occurring Alcohol Use Disorders and Serious Mental Illness. Am J Psychiatry. 2017 Apr 01; 174(4):370-377.
Score: 0.008
-
Karkar R, Zia J, Vilardaga R, Mishra SR, Fogarty J, Munson SA, Kientz JA. A framework for self-experimentation in personalized health. J Am Med Inform Assoc. 2016 May; 23(3):440-8.
Score: 0.007
-
Zeng EY, Vilardaga R, Heffner JL, Mull KE, Bricker JB. Predictors of Utilization of a Novel Smoking Cessation Smartphone App. Telemed J E Health. 2015 Dec; 21(12):998-1004.
Score: 0.007
-
Lowe JM, McDonell MG, Leickly E, Angelo FA, Vilardaga R, McPherson S, Srebnik D, Roll J, Ries RK. Determining ethyl glucuronide cutoffs when detecting self-reported alcohol use in addiction treatment patients. Alcohol Clin Exp Res. 2015 May; 39(5):905-10.
Score: 0.007
-
Leickly E, McDonell MG, Vilardaga R, Angelo FA, Lowe JM, McPherson S, Srebnik D, Roll JM, Ries RK. High levels of agreement between clinic-based ethyl glucuronide (EtG) immunoassays and laboratory-based mass spectrometry. Am J Drug Alcohol Abuse. 2015 May; 41(3):246-50.
Score: 0.007
-
Jones HA, Heffner JL, Mercer L, Wyszynski CM, Vilardaga R, Bricker JB. Web-based acceptance and commitment therapy smoking cessation treatment for smokers with depressive symptoms. J Dual Diagn. 2015; 11(1):56-62.
Score: 0.007
-
Heffner JL, Vilardaga R, Mercer LD, Kientz JA, Bricker JB. Feature-level analysis of a novel smartphone application for smoking cessation. Am J Drug Alcohol Abuse. 2015 Jan; 41(1):68-73.
Score: 0.007
-
Bricker JB, Mull KE, Kientz JA, Vilardaga R, Mercer LD, Akioka KJ, Heffner JL. Randomized, controlled pilot trial of a smartphone app for smoking cessation using acceptance and commitment therapy. Drug Alcohol Depend. 2014 Oct 01; 143:87-94.
Score: 0.006
-
McDonell M, McPherson S, Vilardaga R, Srebnik D, Angelo FN, Leickly E, Saxon AJ, Roll J, Ries R. Preliminary findings: Contingency management targeting psycho-stimulant use results in secondary decreases in smoking for severely mentally ill adults. Am J Addict. 2014; 23(4):407-10.
Score: 0.006